MRNA COVID-19 Vaccination During or Immediately Before Pregnancy Not Linked to Autism or Developmental Disorders in Children, Major Study Reveals

Groundbreaking research presented at the Society for Maternal-Fetal Medicine (SMFM) 2026 Pregnancy Meeting has delivered compelling evidence that receiving an mRNA COVID-19 vaccine shortly before or at any point during pregnancy is not associated with an increased risk of autism or other developmental disorders in children. These pivotal findings offer substantial reassurance to expectant parents and public health officials worldwide, providing critical long-term health data on children whose mothers were vaccinated around the time of conception and throughout their gestation. The study’s conclusions are poised to further solidify confidence in the safety profile of these essential vaccines for one of the most vulnerable populations.

Addressing Long-Standing Public Health Concerns

The introduction of COVID-19 vaccines marked a monumental achievement in global health, yet their rapid development and novel mRNA technology sparked various public concerns, particularly regarding their use in pregnant individuals. Historically, vaccine hesitancy has often converged around pregnancy due to understandable parental instincts to protect unborn children, sometimes fueled by misinformation or a lack of long-term data. Early in the pandemic, while initial safety data for COVID-19 vaccines in pregnancy were reassuring based on observational studies and post-marketing surveillance, comprehensive long-term neurodevelopmental outcomes for offspring were still emerging. This latest study directly addresses a significant component of these concerns by focusing on neurodevelopmental outcomes, specifically autism spectrum disorder and other developmental milestones, in toddlers whose mothers received the mRNA vaccine.

In the United States, the Centers for Disease Control and Prevention (CDC) and leading professional organizations like the American College of Obstetricians and Gynecologists (ACOG) have consistently recommended COVID-19 vaccination for pregnant individuals, citing both mRNA and protein subunit vaccines as safe and effective during all stages of pregnancy. These recommendations are based on accumulating data demonstrating the vaccines’ ability to significantly reduce the risk of severe maternal illness, hospitalization, and adverse pregnancy outcomes such as preterm birth and stillbirth, while also conferring some passive immunity to newborns. However, for many, the absence of specific, long-term neurodevelopmental data for children born to vaccinated mothers remained a point of apprehension. The SMFM 2026 presentation directly fills this critical gap, reinforcing the scientific consensus that the benefits of vaccination far outweigh any perceived risks.

Rigorous Methodology and Participant Cohort

The investigation, a testament to collaborative scientific endeavor, was meticulously conducted by researchers within the Maternal-Fetal Medicine Units (MFMU) Network, a consortium renowned for its high-quality clinical trials and observational studies related to maternal and infant health. The study design was prospective, multi-center, and observational, ensuring a robust approach to data collection and analysis. It spanned nearly a year, from May 2024 to March 2025, allowing for a comprehensive assessment period.

The study cohort comprised 434 children, all evaluated between 18 months and 30 months of age, a crucial developmental window for identifying early signs of autism and other developmental concerns. To ensure scientific rigor and minimize confounding factors, the cohort was evenly divided: 217 children were born to mothers who had received at least one dose of an mRNA COVID-19 vaccine either during pregnancy or within 30 days prior to becoming pregnant. This "30 days prior" window is significant as it captures vaccination events around the periconceptional period, addressing concerns about early embryonic development. The remaining 217 children served as the unvaccinated control group, born to mothers who did not receive an mRNA vaccine during or within 30 days prior to pregnancy.

To achieve an accurate comparison, the research team employed a meticulous matching process. Vaccinated mothers were carefully paired with unvaccinated mothers based on several key demographic and obstetrical factors: the facility where they delivered (e.g., hospital, birth center), the exact date of delivery, their insurance status, and their race. This precise matching strategy aimed to control for potential socioeconomic, healthcare access, and genetic variables that could independently influence child development, thereby isolating the impact of vaccination. Furthermore, the study applied strict exclusion criteria for both groups, omitting pregnancies that ended before 37 weeks (preterm births), those involving multiple babies (twins, triplets, etc.), or those that resulted in a child with a major congenital malformation. These exclusions were vital to focus the study on otherwise healthy, term-born singleton infants, where any subtle neurodevelopmental differences related to vaccination would be more discernible.

Comprehensive Developmental Assessments

A cornerstone of the study’s strength was its multi-faceted approach to assessing child development. When the children reached 1.5 to 2.5 years of age, researchers utilized a suite of well-validated screening tools. The primary instrument was the Ages and Stages Questionnaire Version 3 (ASQ-3), a widely recognized parent-completed developmental screening tool. The ASQ-3 measures progress across five critical developmental domains: communication (language and pre-language skills), gross motor skills (large muscle movements), fine motor skills (small muscle coordination), problem-solving (cognitive abilities), and personal-social interaction (social-emotional development and self-help skills). A score below a certain threshold on any of these scales can indicate a need for further evaluation.

Beyond the ASQ-3, the research team delved deeper into behavioral and developmental patterns by reviewing results from three additional specialized instruments:

1. Child Behavior Checklist (CBCL): This comprehensive questionnaire, completed by parents, assesses a wide range of behavioral and emotional problems, providing insight into internalizing (e.g., anxiety, depression) and externalizing (e.g., aggression, hyperactivity) behaviors.
2. Modified Checklist for Autism in Toddlers, Revised with Follow-up (M-CHAT-R/F): Specifically designed to screen for autism spectrum disorder in toddlers, this tool is highly effective in identifying children at risk for autism and guiding further diagnostic evaluation.
3. Early Childhood Behavior Questionnaire (ECBQ): This questionnaire provides a detailed assessment of temperament in infants and toddlers, including dimensions like activity level, negative emotionality, and effortful control, which can be indicators of broader neurodevelopmental trajectories.

The combination of these tools provided a holistic and robust evaluation of each child’s neurodevelopment, allowing researchers to detect even subtle differences across various domains. The consistent findings across these diverse measures further strengthen the study’s conclusions.

Expert Perspectives on Reassuring Findings

The lead researchers underscored the profound significance of these findings. Dr. George R. Saade, MD, a senior researcher on the study, who serves as Professor and Chair of Obstetrics and Gynecology, and Associate Dean for Women’s Health, at Macon & Joan Brock Virginia Health Sciences at Old Dominion University in Norfolk, VA, articulated the core conclusion: "Neurodevelopment outcomes in children born to mothers who received the COVID-19 vaccine during or shortly before pregnancy did not differ from those born to mothers who did not receive the vaccine." This unequivocal statement provides direct scientific rebuttal to fears linking mRNA vaccination to developmental issues.

Echoing this sentiment, Dr. Brenna L. Hughes, MD, MSc, the Edwin Crowell Hamblen Distinguished Professor of Reproductive Biology and Family Planning and Interim Chair of the Department of Obstetrics and Gynecology at Duke University in Raleigh, NC, also weighed in on the study’s implications. Dr. Hughes emphasized the rigorous nature of the research: "This study, conducted through a rigorous scientific process in an NIH clinical trials network, demonstrates reassuring findings regarding the long-term health of children whose mothers received COVID-19 vaccination during pregnancy." Her statement highlights the credibility imparted by the study’s affiliation with an NIH network, indicating adherence to the highest standards of clinical research. These expert endorsements from leading figures in maternal-fetal medicine underscore the scientific community’s confidence in the study’s methodology and conclusions.

The Broader Public Health Imperative and Context

The significance of this research extends far beyond the immediate findings. It arrives at a crucial juncture for public health messaging and vaccine confidence. From the onset of the COVID-19 pandemic, misinformation and vaccine skepticism have posed substantial challenges to public health efforts. Concerns about vaccine safety in pregnancy, though largely unsubstantiated by initial data, persisted in some segments of the population. This new, robust, long-term data provides an authoritative counter-narrative to such fears, particularly those linking vaccines to autism—a concern that, while thoroughly debunked in the context of other vaccines like MMR, often resurfaces with new vaccine technologies.

The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) funded the study, a testament to its commitment to understanding and promoting the health of mothers and children. The NIH’s involvement not only ensures financial support but also implies rigorous oversight and adherence to ethical research standards, further bolstering the study’s credibility. The authors explicitly noted that their conclusions are their own and do not necessarily reflect the official views of the National Institutes of Health, a standard disclosure that maintains academic independence while acknowledging funding sources.

This study reinforces the critical message that vaccination during pregnancy is a safe and effective strategy not only for protecting the mother from severe COVID-19 illness, which itself can lead to adverse pregnancy outcomes, but also for ensuring the healthy neurodevelopment of her child. The findings are expected to be instrumental in public health campaigns aimed at increasing vaccine uptake among pregnant individuals and those planning pregnancy. Health organizations like the CDC, ACOG, and SMFM will undoubtedly integrate these findings into their updated guidance and patient education materials, providing clinicians with further evidence to confidently recommend vaccination.

Future Directions and Ongoing Vigilance

While the current study provides robust reassurance regarding neurodevelopmental outcomes at 18-30 months of age, the scientific community maintains a commitment to ongoing vigilance. Future research may involve even longer-term follow-up of these cohorts, extending into early childhood and school age, to capture any extremely rare or delayed effects that might not be apparent in toddlerhood. Additionally, studies may explore other specific aspects of child health or examine different populations or vaccine types, although the mRNA vaccines are the most widely used and studied globally.

The oral abstract detailing these pivotal findings, titled "#8 Association between SARS-CoV-2 vaccine in pregnancy and child neurodevelopment at 18-30 months," is scheduled for publication in the February 2026 issue of PREGNANCY, the official peer-reviewed medical journal of the Society for Maternal-Fetal Medicine. Its publication in such a prestigious, specialized journal ensures that the data will be widely accessible and scrutinized by the leading experts in the field, further solidifying its place in evidence-based medicine.

In conclusion, this landmark study provides compelling, long-term evidence that mRNA COVID-19 vaccination during or immediately before pregnancy poses no increased risk for autism or other developmental disorders in children. It stands as a powerful affirmation of vaccine safety, offering invaluable clarity to parents, clinicians, and public health authorities, and reinforcing the critical role of vaccination in safeguarding maternal and child health in the ongoing post-pandemic era.